Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant public health and financial burden. The impending expansion of the treatment labels of the four nonmonitored, fixed-dose oral anticoagulants into the treatment and secondary prophylaxis of VTE will address the need for more-convenient alternatives to current standards of care, and these agents will drive market growth during the forecast period. However, opportunities remain in other underserved VTE indications, including primary prophylaxis of VTE in acute medically ill and ambulatory cancer patients.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 23 country-specific interviews with thought leaders.
Epidemiology: Number of DVT events; number of PE events; number of hospitalization events (orthopedic surgery, major non-orthopedic surgery, minor nonorthopedic surgery, nonsurgical) eligible for VTE acute primary prophylaxis; number of prevalent cases of cancer patients eligible for VTE primary prophylaxis.
Population segments in market forecast: Primary prophylaxis indications (major orthopedic surgery, non-orthopedic surgery, nonsurgical patients, cancer patients eligible for prophylaxis); acute DVT treatment and secondary prophylaxis; acute PE treatment and secondary prophylaxis.
Emerging therapies: Phase II: 1 drug; Phase III/preregistration/registration: 6 drugs. Coverage of select preclinical and Phase I products.
Market forecast features: Using a patient-based model, we forecast drug sales for two market segments: for VTE acute treatment/secondary prophylaxis and VTE primary prophylaxis through 2022.